Phase IPeptide
Compound 61488
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061488
Risk Class
MODERATE
Last Audit
Mar 5, 2108
Research Abstract
Peptide candidate engineered for oncology adjuvant initiatives with automated dossier coverage.
Compound 61488 is a peptide asset inside peptide innovation track initiatives, optimized for oncology adjuvant and inflammation control.
The dossier currently sits in phase i with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061488 with updates logged 2108-03-05.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Oncology adjuvantInflammation control
Nomenclature
CX-61488Peptide Program 61488
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061488
- [2] Operations Pulse • Peptide innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61488